Company Overview

Cencora is a leading global pharmaceutical solutions organization dedicated to improving the lives of people and animals worldwide. Formerly known as AmerisourceBergen Corporation, the company successfully completed its name and stock ticker change to Cencora (NYSE: COR) on August 30, 2023. Cencora plays a critical role in the pharmaceutical supply chain, connecting manufacturers, healthcare providers, and patients to ensure access to essential therapies.

Business Overview

As one of the "big three" pharmaceutical wholesale distributors globally, Cencora acts as a vital link, ensuring that manufacturers, providers, and patients receive the necessary therapies when and where they are needed. Alongside McKesson and Cardinal Health, Cencora constitutes over 90% of the U.S. pharmaceutical wholesale industry.

#### Key Services and Capabilities

- Pharmaceutical Distribution:

- Sources and distributes a wide array of pharmaceutical products across the United States and internationally.

- Serves diverse clients including acute care hospitals, health systems, independent and chain retail pharmacies, mail-order pharmacies, medical clinics, and long-term care facilities.

- Offers a comprehensive product range through wholesale distribution solutions, encompassing brand and generic drugs, consumer products, and hospital supplies.

- Specialty Services:

- Manages and delivers specialized products, including cutting-edge cell and gene therapies and biosimilars.

- Provides integrated services such as pharmacy management, staffing, consulting, supply management software, packaging solutions, clinical trial support, and commercialization support services.

- Delivers commercialization services tailored for pharmaceutical and medical device manufacturers, offers global specialty drug logistics via World Courier, and facilitates animal health product distribution through MWI Animal Health.

Global Footprint

Cencora is a significant global player, ranked #11 on the Fortune 500. The company operates over 1,300 global office locations and maintains a local presence in more than 50 countries. Cencora unifies its 46,000 employees across various global business segments under a single, cohesive identity.

A key expansion in its international reach occurred in 2021 with the acquisition of Alliance Healthcare, a prominent drug wholesaler in Europe, further strengthening its global distribution network.

Financial Performance

#### Recent Quarterly Results

- Q3 FY2025 Performance:

- Revenue: $80.7 billion, an increase of 8.7% year-over-year.

- GAAP diluted EPS: $3.52.

- Adjusted diluted EPS: $4.00.

- Q2 FY2025 Performance:

- Revenue: $75.5 billion, an increase of 10.3% year-over-year.

- GAAP diluted EPS: $3.68.

- Adjusted diluted EPS: $4.42.

- Q1 FY2025 Performance:

- Revenue: $81.5 billion, an increase of 12.8% year-over-year.

- GAAP diluted EPS: $2.50.

- Adjusted diluted EPS: $3.73.

#### Annual Results

- FY2024 Performance:

- Revenue: $294.0 billion, a 12.1% increase year-over-year.

- GAAP diluted EPS: $7.53.

#### Market Capitalization and Guidance

As of September 2025, Cencora's market capitalization stands at $53.655 billion. The company has raised its adjusted diluted EPS guidance for fiscal year 2025 to a range of $15.85 to $16.00. Cencora anticipates revenue growth of approximately 9% for the fiscal year, with operating income growth expected to be between 15% and 16%.

Strategic Initiatives

Cencora remains strategically focused on its core priorities, which include driving digital transformation and making growth-oriented investments. These initiatives are designed to solidify its position as the partner of choice within the pharmaceutical industry. The company continues to invest significantly in its foundational pharmaceutical distribution business while simultaneously expanding its platform of pharma and biopharma services to foster pharmaceutical innovation and improve global access to critical treatments.

Corporate Social Responsibility

In commemoration of its rebranding milestone, Cencora announced a $5 million donation to the Cencora Impact Foundation, an independent not-for-profit charitable organization. Furthermore, Cencora Ventures, the company's dedicated corporate venture fund, has committed to donating 10% of its future realized profits to support the vital efforts of the Cencora Impact Foundation.

Cencora continues to be an indispensable player in the global pharmaceutical ecosystem, leveraging its extensive network and profound expertise to enhance healthcare access and improve patient outcomes worldwide.